🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 4 of 151

  1. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Salivary Gland Carcinoma

    phase 2 small molecule terminated

    1 trial

  2. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  3. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Pancreatic Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  4. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Cancer

    phase 2 small molecule active

    1 trial

  5. 90 grams of Crystalline Lactulose

    CUMBERLAND PHARMACEUTICALS INC

    Colonoscopy Preparation

    phase 2 small molecule completed

    1 trial

  6. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Hemostasis

    phase 2 small molecule completed

    1 trial

  7. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Bone Mineral Density

    phase 2 small molecule completed

    1 trial

  8. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Migraine

    phase 2 small molecule completed

    1 trial

  9. A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

    Hoffmann-La Roche

    Advanced or metastatic squamous cell carcinoma of the esophagus

    phase 2 other active

    1 trial

  10. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi-aventis Healthcare Pty Ltd

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  11. A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress

    Seaport Therapeutics

    Major Depressive Disorder (MDD), with or without Anxious Distress

    phase 2 other active

    1 trial

  12. A Clinical Trial for Patients with Advanced Cancers

    Corbus Pharmaceuticals Holdings

    Advanced Solid tumour

    phase 2 other active

    1 trial

  13. A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)

    Merck Sharp and Dohme

    Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)

    phase 2 other active

    1 trial

  14. A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)

    Takeda

    Idiopathic Hypersomnia (IH)

    phase 2 other active

    1 trial

  15. A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults with Alcohol-related Liver Disease (ALD)

    GlaxoSmithKline

    Liver Diseases, Alcoholic

    phase 2 other active

    1 trial

  16. A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

    Ningbo Cancer Hospital

    Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

    phase 2 other active

    1 trial

  17. A Master Ganoderma Detox Tea

    Hong Kong Baptist University

    Eczema

    phase 2 other active

    1 trial

  18. A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 other active

    1 trial

  19. A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)

    Tyra Biosciences

    Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations

    phase 2 other active

    1 trial

  20. A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults

    phase 2 other active

    1 trial

  21. A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)

    GlaxoSmithKline

    Neoplasms, Prostate

    phase 2 other active

    1 trial

  22. A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

    Incyte

    Anaemia associated with myelofibrosis

    phase 2 other active

    1 trial

  23. A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  24. A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment

    Shanghai Antengene Corporation Limited

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  25. A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

    phase 2 other active

    1 trial

  26. A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 other active

    1 trial

  27. A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants with Hunter Syndrome

    Denali Therapeutics

    Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II])

    phase 2 other active

    1 trial

  28. A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy

    Solid Biosciences

    Duchenne muscular dystrophy

    phase 2 other active

    1 trial

  29. A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

    uniQure biopharma B.V.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 other active

    1 trial

  30. A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 other active

    1 trial

  31. A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 years of age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 other active

    1 trial

  32. A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 other active

    1 trial

  33. A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors

    Centessa Pharmaceuticals plc

    Advanced solid tumors

    phase 2 other active

    1 trial

  34. A Phase 1b study to investigate safety and tolerability of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome (CMS)

    argenx

    congenital neuromuscular disorders

    phase 2 other active

    1 trial

  35. A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors

    GlaxoSmithKline

    Gastrointestinal Neoplasms

    phase 2 other active

    1 trial

  36. A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  37. A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

    Tyra Biosciences

    Non-muscle invasive bladder cancer (NMIBC)

    phase 2 other active

    1 trial

  38. A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

    Lacuna Pharma Pty Ltd

    Primary Hyperoxaluria

    phase 2 other active

    1 trial

  39. A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  40. A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)

    Alphapharm Pty Ltd

    Congenital Hyperinsulinism (CHI)

    phase 2 other active

    1 trial

  41. A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis

    Arcturus Therapeutics Holdings

    Cystic Fibrosis

    phase 2 other active

    1 trial

  42. A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic Syndrome.

    GlaxoSmithKline

    Myelodysplastic Syndrome

    phase 2 other active

    1 trial

  43. A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)

    GlaxoSmithKline

    Multiple Myeloma

    phase 2 other active

    1 trial

  44. A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)”

    Incyte

    Ovarian Cancer

    phase 2 other active

    1 trial

  45. A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Karyopharm Therapeutics Inc

    Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL

    phase 2 other active

    1 trial

  46. A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

    GlaxoSmithKline

    Ovarian Neoplasms

    phase 2 other active

    1 trial

  47. A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

    The George Institute

    Patients with HER2Positive Advanced Breast Cancer

    phase 2 other active

    1 trial

  48. A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer

    Novartis Pharmaceuticals

    Metastatic neuroendocrine prostate cancer

    phase 2 other active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.